Details for Patent: 11,963,958
✉ Email this page to a colleague
Which drugs does patent 11,963,958 protect, and when does it expire?
Patent 11,963,958 protects GAVRETO and is included in one NDA.
This patent has thirty-one patent family members in twenty-four countries.
Drugs Protected by US Patent 11,963,958
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharms | GAVRETO | pralsetinib | CAPSULE;ORAL | 213721-001 | Sep 4, 2020 | RX | Yes | Yes | 11,963,958 | ⤷ Subscribe | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE) | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,963,958
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019247766 | ⤷ Subscribe | |||
| Brazil | 112020020273 | ⤷ Subscribe | |||
| Canada | 3096043 | ⤷ Subscribe | |||
| Chile | 2020002544 | ⤷ Subscribe | |||
| China | 110891573 | ⤷ Subscribe | |||
| Costa Rica | 20200522 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
